COTA, Inc.

@cotahealthcare

COTA brings clarity to cancer care by organizing fragmented, real-world data to ensure that everyone touched by cancer has a clear path to the right care.

New York, NY
Vrijeme pridruživanja: rujan 2014.

Tweetovi

Blokirali ste korisnika/cu @cotahealthcare

Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @cotahealthcare

  1. Prikvačeni tweet
    3. velj

    Novel sources & growing volumes of data are changing the way drugs are developed, evaluated & brought to market. In the spirit of collaboration, COTA invited our partners from & to share their unique perspectives as early adopters of :

    Poništi
  2. prije 15 sati

    . is leading the race in the development of drugs, says a new piece. Learn more about the company's anti-BCMA drugs & new therapies coming down the pipeline:

    Poništi
  3. proslijedio/la je Tweet

    What’s it like to be rejected from a clinical trial? “The feeling like we’re able to fight, along with that hope — we felt like that was swept out from under us. And let’s face it: With Huntington’s, it’s a hopeless disease.” By ⁦

    Poništi
  4. proslijedio/la je Tweet

    The two Q&As from this story are open access, too. Jeff Allen (): & all ten "frenemy" health care research organizations:

    , , i još njih 7
    Prikaži ovu nit
    Poništi
  5. 4. velj

    Today, COTA is recognizing – to raise awareness about prevention, detection & treatment. Since our beginning, COTA has been tirelessly working to improve the lives of cancer patients, and we will continue to do so by helping to bring clarity to .

    Poništi
  6. 4. velj

    At , , COTA’s VP of Life Sciences, spoke with on the growing understanding & acceptance of and how it is used in research. Hear his insight below as it relates to clinical trials & recent initiatives:

    Poništi
  7. 3. velj

    In a joint effort with , is expanding access to navigation & support tools to make it easier for patients to enroll and maintain participation in clinical trials:

    Poništi
  8. 2. velj

    With no formal standards for what makes real-world evidence "regulatory grade," looks at if and how this information can be used in the decision making process:

    Poništi
  9. proslijedio/la je Tweet
    21. sij
    Poništi
  10. 31. sij

    A recent report from the ONC for HIT found that only 58% of recently diagnosed cancer were offered access to their online , and only 40% of actually viewed their record:

    Poništi
  11. proslijedio/la je Tweet

    AI in clinical trials: Andrew Norden CMO and Tufia Haddad unpack the issues and outline progress in using big data and in for cancer

    Poništi
  12. proslijedio/la je Tweet
    26. sij

    Why big pharma sees a remedy in data and AI

    Poništi
  13. 30. sij

    – Did you hear COTA, Inc. was named as one of 's 2020 Fierce 15 Companies? Learn what makes us fierce below:

    Poništi
  14. proslijedio/la je Tweet
    22. sij
    Poništi
  15. 29. sij

    Is all created equal? A recent article looks at the use of to support more efficient clinical trials. , who leads the Global Medical Epidemiology & Big Data Analysis group at , spoke around their work to harness RWD:

    Poništi
  16. proslijedio/la je Tweet
    16. sij

    “This is a big step forward in personalizing cancer treatment and ensuring better patient outcomes,” said Professor Lim Chwee Teck, Mechanobiology Institute, NUS Biomedical Engineering.

    Poništi
  17. proslijedio/la je Tweet
    15. sij

    “Platform business models have been a force of disruption in many sectors, rapid digitalization of is affording us unprecedented opportunity to solve complex medical problems and improve lives of people on a global scale” JH

    Poništi
  18. 26. sij

    At , researchers presented a post-marketing study of tisagenlecleucel in the real-world setting. As they found real-world efficacy & safety was comparable to the JULIET trial, how could earlier use of transform clinical research?

    Poništi
  19. proslijedio/la je Tweet
    15. sij

    Many cancer patients struggle with out-of-pocket cancer care expenses, with costs reaching nearly $150 billion nationally per year.

    Poništi
  20. 24. sij

    As technology becomes more advanced in , AMIA offers guidance to the NIH & FDA on sharing and how to regulate clinical decision support software:

    Poništi

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.

    Možda bi vam se svidjelo i ovo:

    ·